A meta-analysis of 10,013 patients showed semaglutide reduced major cardiac events by 21% (HR 0.79), and predictive modeling forecasts the SOUL oral semaglutide trial will reach its endpoint by 3.78 years — earlier than the planned 5.4 years.
HR 0.79 for MACEPooled semaglutide data showing 21% reduction in major cardiac events, predicting early termination of the SOUL oral semaglutide trial
What the researchers found
Pooled analysis of semaglutide trials showed HR 0.79 (95% CI: 0.69-0.91) for MACE. Predictive modeling forecasts the 9,642-patient SOUL trial will achieve its primary endpoint by 3.78 years, suggesting early termination.
Why it matters
If confirmed, oral semaglutide's cardiovascular benefits would make an effective heart-protective diabetes and weight-loss drug available in pill form — dramatically improving access compared to injectable formulations and potentially changing prescribing patterns.
The numbers in context
SOUL is a multicenter, double-blind, placebo-controlled RCT. The primary endpoint is major adverse cardiac events (MACE).
How the study worked
Random-effects meta-analysis of prior semaglutide RCTs pooling hazard ratios. Matched placebo-arm cardiovascular event rates with SOUL trial assumptions to build a predictive model for trial duration and primary events.
Who was studied
Patients with type 2 diabetes at cardiovascular risk
What this study cannot tell us
Predictive models depend on assumptions that may not hold. The meta-analysis pooled injectable semaglutide data to predict oral semaglutide outcomes. Real-world trial dynamics (dropout, protocol amendments) can affect actual timelines. This is a prediction, not a result.
How to read the evidence
Moderate evidence for the meta-analysis component; preliminary for the predictive model. The prediction awaits validation from the actual SOUL trial results.
When this study was published
Published in 2024. The SOUL trial was ongoing at time of publication.
The bigger picture
Cardiovascular outcome trials (CVOTs) are enormously expensive and lengthy. If predictive models can accurately forecast trial outcomes, they could reduce costs and accelerate bringing beneficial drugs to patients. This work also reinforces the robustness of semaglutide's cardiac benefits across formulations.
Questions still open
- Will the actual SOUL trial results match this prediction?
- Could oral semaglutide show different cardiovascular effect sizes than injectable forms?
- How reliable are predictive models for other ongoing cardiovascular outcome trials?
Common questions
What is the SOUL trial?
Why would a trial end early?
Read the original research
Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study.
Diabetes therapy : research, treatment and education of diabetes and related disorders, 15(10), 2199-2209
Citation
Sinha, Binayak; Ghosal, Samit. (2024). Forecasting Trial Milestones: A Predictive Analysis for Early Termination of the SOUL Study.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 15(10), 2199-2209. https://doi.org/10.1007/s13300-024-01635-1